Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JORGE M VENEREO

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1144299009
CMS profile
324488
Location
DORAL, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$95.63

5 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $95.63 5

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Janssen Pharmaceuticals, Inc $68.88 4
Boehringer Ingelheim Pharmaceuticals, Inc. $26.75 1

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JORGE M VENEREO

NPI 1144299009 · CMS profile ID 324488

Allopathic & Osteopathic Physicians / Internal Medicine

DORAL, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1144299009?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JORGE M VENEREO, NPI 1144299009, CMS profile ID 324488. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1144299009?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). JORGE M VENEREO, NPI 1144299009, CMS profile ID 324488. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1144299009?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
JORGE M VENEREO, NPI 1144299009, CMS profile ID 324488, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1144299009?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

5 matching records · $95.63 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 5 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–5 of 5.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Pharmaceuticals, Inc $13.8808/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787921203 CMS
Janssen Pharmaceuticals, Inc $17.8705/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787921205 CMS
Janssen Pharmaceuticals, Inc $17.8705/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787921201 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $26.7503/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763507670 CMS
Janssen Pharmaceuticals, Inc $19.2602/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787921207 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $34.17 2
PY2020 $83.58 5
PY2021 $95.63 5
PY2022 $125.00 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022
Generated from
OP_DTL_GNRL_PGYR2022_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $978,346.35 79
PY2024 Principal investigator $750,186.73 535
PY2023 Recipient $250.00 1
PY2023 Principal investigator $1,161,263.89 753
PY2022 Recipient $450.00 1
PY2022 Principal investigator $433,849.06 425
PY2021 Recipient $437.46 1
PY2021 Principal investigator $229,625.48 182
PY2020 Principal investigator $282,764.54 64
PY2019 Principal investigator $543,958.67 209

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

64 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AbbVie Inc. $871.20 12/30/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
M16-100 No dispute reported 06/30/2026 721202603
Principal investigator 1 AbbVie Inc. $247.00 12/16/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
M16-100 No dispute reported 06/30/2026 721200753
Principal investigator 1 AbbVie Inc. $1,051.60 12/15/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
M19-161 No dispute reported 06/30/2026 721200475
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $401.40 12/03/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 740110615
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,392.80 12/03/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 740110617
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $125.00 12/03/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 740110619
Principal investigator 1 AbbVie Inc. $2,720.40 12/01/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
M16-100 No dispute reported 06/30/2026 721197993
Principal investigator 1 AbbVie Inc. $3,117.42 12/01/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
M19-161 No dispute reported 06/30/2026 721198331
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,320.70 11/05/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 740110613
Principal investigator 1 AbbVie Inc. $7,869.00 10/29/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
M16-100 No dispute reported 06/30/2026 721192781
Principal investigator 1 AbbVie Inc. $2,355.60 10/29/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
M19-161 No dispute reported 06/30/2026 721193323
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,494.20 10/28/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 740110611
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $223.00 10/22/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 740110609
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $223.00 10/15/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 740110603
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,500.00 10/15/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 740110605
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,800.00 10/15/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 740110607
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,952.00 10/08/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 740110601
Principal investigator 1 AbbVie Inc. $1,051.20 09/30/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
M16-100 No dispute reported 06/30/2026 721188019
Principal investigator 1 AbbVie Inc. $380.91 09/30/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
M19-161 No dispute reported 06/30/2026 721188871
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,415.40 09/17/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 740110599
Principal investigator 1 AbbVie Inc. $1,118.90 09/10/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
M16-100 No dispute reported 06/30/2026 721185625
Principal investigator 1 AbbVie Inc. $7,033.60 08/28/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
M16-100 No dispute reported 06/30/2026 721182873
Principal investigator 1 AbbVie Inc. $1,354.61 08/28/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
M19-161 No dispute reported 06/30/2026 721183463
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,908.40 08/26/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 740110595
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $223.00 08/26/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 740110597
Principal investigator 1 AbbVie Inc. $7,914.40 07/31/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
M19-161 No dispute reported 06/30/2026 721178837
Principal investigator 1 AbbVie Inc. $4,052.50 07/30/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
M16-100 No dispute reported 06/30/2026 721177559
Principal investigator 1 AbbVie Inc. $927.80 07/29/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
M16-100 No dispute reported 06/30/2026 721177057
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,827.80 07/29/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 740110593
Principal investigator 1 Eisai Inc. $53,730.80 07/16/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749108547
Principal investigator 1 AbbVie Inc. $4,993.30 07/02/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
M19-161 No dispute reported 06/30/2026 721174645
Principal investigator 1 Ferring Pharmaceuticals AS $43,290.20 07/01/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 721460027
Principal investigator 1 AbbVie Inc. $7,139.30 06/30/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
M16-100 No dispute reported 06/30/2026 721172891
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,730.80 06/24/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 740110591
Principal investigator 1 AbbVie Inc. $1,873.90 05/28/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
M16-100 No dispute reported 06/30/2026 721167807
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,665.00 05/27/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 740110589
Principal investigator 1 AbbVie Inc. $2,257.30 05/26/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
M16-100 No dispute reported 06/30/2026 721166977
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,703.00 05/21/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 740110587
Principal investigator 1 AbbVie Inc. $2,077.90 05/08/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
M16-100 No dispute reported 06/30/2026 721165681
Principal investigator 1 AbbVie Inc. $11,178.00 05/06/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
M16-100 No dispute reported 06/30/2026 721165115
Principal investigator 1 AbbVie Inc. $6,046.60 04/30/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
M16-100 No dispute reported 06/30/2026 721163203
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,354.40 04/22/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 740110583
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,766.00 04/22/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 740110585
Principal investigator 1 AbbVie Inc. $5,000.00 04/20/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
M19-161 No dispute reported 06/30/2026 721161329
Principal investigator 1 AbbVie Inc. $2,500.00 04/20/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
M19-161 No dispute reported 06/30/2026 721161331
Principal investigator 1 Eisai Inc. $1,175.00 03/31/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749108249
Principal investigator 1 AbbVie Inc. $3,783.50 03/30/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
M16-100 No dispute reported 06/30/2026 721157825
Principal investigator 1 AbbVie Inc. $1,111.10 03/27/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
M16-100 No dispute reported 06/30/2026 721157331
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,922.40 03/26/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 740110581
Principal investigator 1 Eisai Inc. $1,000.00 03/17/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749107867
Principal investigator 1 Ferring Pharmaceuticals AS $435.00 03/09/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 721459685
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $6,146.00 02/19/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 740110579
Principal investigator 1 Eisai Inc. $2,722.00 02/07/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749107809
Principal investigator 1 Eisai Inc. $2,722.00 02/07/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749107811
Principal investigator 1 Eisai Inc. $2,722.00 02/07/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749107813
Principal investigator 1 Eisai Inc. $2,722.00 02/07/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749107815
Principal investigator 1 Eisai Inc. $2,722.00 02/07/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749107817
Principal investigator 1 Eisai Inc. $2,722.00 02/07/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749107819
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,125.60 01/22/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 740110577
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $223.00 01/17/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 740110575
Principal investigator 1 Eli Lilly and Company $2,542.50 01/16/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
AN OPEN LABEL, LONG TERM, SAFETY STUDY OF LASMIDITAN 100 MG AND 200 MG IN THE ACUTE TREATMENT OF MIGRAINE GLADIATOR No dispute reported 06/30/2026 728747073
Principal investigator 1 AbbVie Inc. $901.50 01/13/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
M16-100 No dispute reported 06/30/2026 721145103
Principal investigator 1 Ferring Pharmaceuticals AS $3,183.00 01/07/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 721459467
Principal investigator 1 Novartis Pharmaceuticals Corporation $13,704.60 01/02/2020 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
AN OPEN-LABEL EXTENSION TRIAL OF THE PHASE III LIPID-LOWERING TRIALS TO ASSESS THE EFFECT OF LONG TERM DOSING OF INCLISIRAN GIVEN AS SUBCUTANEOUS INJECTIONS IN SUBJECTS WITH HIGH CARDIOVASCULAR RISK AND ELEVATED LDL-C No dispute reported 06/30/2026 965470905